Pharmacological Strategies for Treating Major Depression
Summary
Major depression remains a leading contributor to global disability, driving continuous efforts to refine pharmacological treatments. Traditional therapies focus on augmenting monoaminergic transmission, most notably by inhibiting the reuptake of serotonin, noradrenaline or both. Selective serotonin reuptake inhibitors (SSRIs) and serotonin–noradrenaline reuptake inhibitors (SNRIs) are first-line agents, while tricyclic antidepressants and monoamine oxidase inhibitors serve in refractory cases. More recently, agents targeting glutamatergic neurotransmission have emerged; ketamine and its enantiomer esketamine, acting as N-methyl-D-aspartate (NMDA) receptor antagonists, demonstrate rapid relief in treatment-resistant depression. Novel compounds aim to modulate receptor subtypes within the serotonin family, to enhance neuroplasticity via brain-derived neurotrophic factor (BDNF) signalling, or to attenuate inflammatory pathways implicated in depressive pathology. Efforts to personalise treatment now consider genetic, developmental and comorbid medical factors to optimise efficacy and minimise side effects. The field increasingly integrates structural biology, medicinal chemistry and systems pharmacology to develop multi-target ligands and combination regimens that accelerate onset of action and sustain remission without compromising tolerability.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Pharmacological Strategies for Treating Major Depression publication trend
The graph below shows the total number of articles in pharmacological strategies for treating major depression across all publications each year (not limited to Nature Index journals).
Technical terms
Selectivity: Preference of a drug for one receptor subtype over others, minimising off-target effects.
Structure–activity relationship (SAR): Correlation between chemical structure modifications and changes in biological activity.
Glutamatergic modulation: Pharmacological intervention of glutamate receptors, notably NMDA receptors, to influence synaptic plasticity.
BDNF: Brain-derived neurotrophic factor, a protein critical for neuronal growth, survival and synaptic plasticity.
5-HT1A receptor: A subtype of serotonin receptor involved in mood regulation and target for partial agonists in depression therapy.
Neuroinflammation: Immune-related processes in the central nervous system that can contribute to depressive symptoms.
References
- Imidazoles as Serotonin Receptor Modulators for Treatment of Depression: Structural Insights and Structure–Activity Relationship Studies. Pharmaceutics (2023).
- Design, synthesis, and biological evaluation of piperazine derivatives involved in the 5-HT1AR/BDNF/PKA pathway. Journal of Enzyme Inhibition and Medicinal Chemistry (2023).
- The treatment of depression — searching for new ideas. Frontiers in Pharmacology (2022).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.